Capital, M&A & Industry Strategy
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
Capital, M&A & Industry Strategy
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
According to the company, the funds will support the next phase of its growth in enabling autonomous science in labs and biopharmaceutical companies using its AI and robotics systems.
The post Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure appeared first on GEN – Genetic Engineering and Biotechnology News.
Opentrons Labworks has raised $40 million from a Series E financing round led by healthcare investor Avego, with additional investment from BroadOak Capital Partners. The company has said that it plans to use the capital to scale its robotics, software, and data infrastructure tools.
Specifically, the funds will support the company’s efforts to design artificial intelligence and robotics systems that work together to design, execute, and learn from scientific experiments. This includes investing in AI-driven experimental execution, extending its automation capabilities, and expanding into new markets and geographies.
Additionally, the funds will allow Opentrons to enable faster protocol development through its software and AI, expand capabilities across its robots and instruments, and provide deeper integration of its tools into the broader lab automation ecosystem.
“Drug developers and AI companies alike are moving experimental work forward toward automated workflows that generate usable data,” said James Flexner, managing partner at Avego. “We see a significant opportunity for autonomous science to converge around Opentrons’ platform.” James Atwood, PhD, Opentrons’ CEO, added “we made lab automation accessible for any lab, and our systems are built for AI to run experiments directly. That is why autonomous science is standardizing on Opentrons.”
Opentrons reports that to date, it has deployed over 11,000 robots to laboratories in over 80 countries. Its customer base includes academic groups, diagnostic labs, and global pharmaceutical companies, Earlier this year, the company announced that it is using Nvidia’s Isaac and Cosmos AI platforms to generate training data needed to develop and deploy physical AI-enabled laboratory robotics.
The post Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure appeared first on GEN - Genetic Engineering and Biotechnology News.
Capital, M&A & Industry Strategy
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s commercial capabilities, executives said on Friday as they reported third-quarter earnings.
Capital, M&A & Industry Strategy
Anthropic’s historic IPO; Akeso’s big clinical showing
Anthropic is setting the stage for the largest IPO in history and Akeso has been touting its latest positive results for its buzzy bispecific.
Anthropic is setting the stage for the largest IPO in history and Akeso has been touting its latest positive results for its buzzy bispecific.
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Postmarketing Requirements and Commitments: Searchable Database
FDA Rationale for Breakpoints Recognition Decision: Minocycline for Stenotrophomonas maltophilia
No Nonsense: David Liu Lauds Progress in Disease-Agnostic Gene Editing at ESGCT
-
Uncategorized7 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized6 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized5 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech7 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology7 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read